Tables
- Table 1. Completed clinical trials in idiopathic pulmonary fibrosis
Drug Mechanism of Action IFIGENIA [20] NAC Antioxidant PANTHER-IPF [21] Prednisone
Azathioprine
NACAntioxidant
ImmunosuppressionTaniguchi [22] Pirfenidone Antifibrotic CAPACITY 1 [23] Pirfenidone Antifibrotic CAPACITY 2 [23] Pirfenidone Antifibrotic ACE-IPF [24] Warfarin Anticoagulant TOMORROW [25] BIBF 1120 Tyrosine-kinase inhibitor Daniels [26] Imatinib mesylate Tyrosine-kinase inhibitor STEP-IPF [27] Sildenafil Phosphodiesterase-5 inhibitor BUILD-1 [28] Bosentan Endothelin-receptor antagonist BUILD-3 [29] Bosentan Endothelin-receptor antagonist ARTEMIS-IPF [30] Ambrisentan Endothelin-receptor antagonist MUSIC-IPF [31] Macitentan Endothelin-receptor antagonist Raghu [32] IFN-γ Immunomodulation INSPIRE [33] IFN-γ Immunomodulation NAC: N-acetyl-cysteine; IFN: interferon.
- Table 2. Ongoing clinical trials in idiopathic pulmonary fibrosis
Trial# Drug Mechanism of action ASCEND (NCT01366209) Pirfenidone Antifibrotic NCT01335477 BIBF 1120 Tyrosine-kinase inhibitor NCT01335464 BIBF 1120 Tyrosine-kinase inhibitor NCT01266135 QAX576 Anti-IL-13 monoclonal antibody NCT00786201 CNTO 888 Anti-CCL-2 monoclonal antibody NCT01262001 FG-3019 Anti-CTGF antibody NCT01362231 AB0024 Anti-LOXL2 monoclonal antibody NCT01385644 MSCs Epithelial tissue repair MSC: mesenchymal stem cell; IL: interleukin; CCL: chemokine (C–C motif) ligand; CTGF: connective tissue growth factor; LOXL: lysyl oxidase-like. #: identifier numbers are provided for http://clinicaltrials.gov/
- Table 3. Pharmacological treatments in idiopathic pulmonary fibrosis (IPF)
Strong no recommendation Corticosteroid monotherapy Colchicine Cyclosporin A A combination of corticosteroids and immunomodulatory therapy Interferon-γ-1b Bosentan Etanercept Weak yes recommendation Corticosteroids in patients with acute exacerbation Treatment of asymptomatic gastro-oesophageal reflux Weak no recommendation Combination of prednisone, azathioprine and NAC: needs to be updated Monotherapy with NAC: further update pending Pirfenidone: needs to be updated Anticoagulants: needs to be updated PH associated with IPF: needs to be updated NAC: N-acetyl-cysteine; PH: pulmonary hypertension.
Vol 22 Issue 129
Table of Contents
Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future
